Zevra Therapeutics reported exceptionally strong financial results for the fiscal year 2025, highlighted by a massive 350% increase in revenue to $106.5 million. The company's performance was primarily driven by the successful commercial launch and rapid adoption of Miplyffa, a treatment for ultra-rare diseases. GAAP earnings per share (EPS) reached $1.40, marking a significant milestone in the company's transition to profitability. Growth was further supported by expanded insurance coverage and strategic diagnostic initiatives that facilitated patient access to the new therapy. Despite the robust financial figures, the stock continues to trade at a discounted forward P/E multiple of 16.9x. This valuation reflects market caution regarding the long-term sustainability of recent earnings growth and one-time income components.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis